 Sydney, AUSTRALIA, Dec. 30, 2020 GLOBE NEWSWIRE -- Immutep Limited ASX: IMM; NASDAQ: IMMP Immutep or the Company, a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is pleased to announce the grant of patent number 10,874,713 entitled Combined Preparations for the Treatment of Cancer or Infection by the United States Patent Trade Mark Office. 